معرفی
Prof. Dr. Roger Schibli is a Full Professor at the Department of Chemistry and Applied Biosciences at ETH Zurich and Head of the Institute of Pharmaceutical Sciences. Since 2010, he has led the Center for Radiopharmaceutical Science (CRS), a collaboration between ETH Zurich and the Paul Scherrer Institute. His academic journey began with a chemistry degree from the University of Basel, followed by a PhD at the Paul Scherrer Institute (1993-1996) and a postdoctoral fellowship at the University of Missouri-Columbia.
Prof. Schibli’s research focuses on targeted tumor diagnostics and therapy using radiolabeled compounds. His group develops and optimizes radiopharmaceuticals for preclinical and clinical applications, emphasizing PET and SPET imaging and the production of medically relevant radionuclides at ETH Zurich’s cyclotron and neutron facilities. Key areas include radioimmunotherapy, albumin-binding ligands, and Ace-2 targeting tracers for diseases like cancer and Alzheimer’s.
The 15 most recent publications highlight a shift toward Terbium-161 for radiotherapy, Folate-based theragnostics, and novel conjugation methods. These works span tumor-targeted alpha therapy, PET tracer development for neurodegenerative diseases, and optimization of radioligands (e.g., PSMA, uPAR) for prostate and ovarian cancer. His group also explores transglutaminase-mediated conjugation for antibody-drug delivery and multi-parameter optimization of brain imaging agents.
Prof. Schibli’s team operates within the Center for Radiopharmaceutical Science (CRS), leveraging infrastructure at ETH Zurich and the Paul Scherrer Institute. Collaborations with Roche and other industry partners underscore his focus on translating academic research into clinical applications. His work addresses challenges in radiolabeled compound stability, kidney uptake reduction, and radiosensitizing strategies to improve therapy efficacy.
